Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Tacit Therapeutics logo — company profile

Tacit Therapeutics

Founded 2021 United States South San Francisco, United States 13 employees Venture round Total: $9.75M Biotechnology, Health Care

General Information

Company Name Tacit Therapeutics
Founded Year 2021
Location United States South San Francisco, United States
Employees 13
Industries Biotechnology, Health Care
Funding Stage Venture round
Business Model B2B
Revenue Model Licensing, Performance Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Tacit Therapeutics. To contact Tacit Therapeutics, visit tacittx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tacit Therapeutics compare?

A PDF of Tacit Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tacit Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Tacit Therapeutics

Tacit Therapeutics is an innovative player in the Biotechnology and Health Care sectors, established in 2021. The company is addressing critical unmet needs by developing RNA-targeting treatments for severe diseases. Tacit Therapeutics' approach involves using pre-existing components of human cells, potentially offering a revolutionary method to repair mutated genes that is inherently non-immunogenic and broadly applicable.

Based in the United States, Tacit Therapeutics is positioning itself as a leader in gene therapy innovation. Their recent investment milestone demonstrates market confidence in their disruptive potential. On June 8, 2022, the company secured a $9.50M venture round investment from Eisai Innovation Inc, showcasing strategic support from established industry participants. With such backing, Tacit Therapeutics is poised for impactful growth, underlining its potential appeal to investors focused on groundbreaking advancements in healthcare.

Business keywords: RNA-targeting treatments, gene therapy, genetic diseases, RNA repair, cellular therapy, genetic mutations, non-immunogenic treatments, biomedical research, therapeutics, medical innovation

Services & Products

RNA trans-splicing therapies
Splicing-Directed Repair technology

Target Customers

patients with genetic diseases healthcare providers biotech and pharmaceutical collaborators

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $9.50M 1
Eisai Innovation Inc
Eisai Innovation Inc
08 Jun 2022
Grant $255.73K 1
National Science Foundation
National Science Foundation
30 Jun 2021

Tacit Therapeutics Alternatives & Competitors

View All Alternatives
Tacit Therapeutics vs
Alltrna
Alltrna United States

The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potent...

Series B
49 employees
Biotechnology, Health Care
Tacit Therapeutics vs
Orchard Therapeutics - U.S.
Orchard Therapeutics - U.S. United Kingdom

Dedicated to transforming the lives of patients with severe and other genetic diseases through innov...

Post-IPO Equity
238 employees
Biotechnology, Health Care
Tacit Therapeutics vs
ADARx Pharmaceuticals Inc.
ADARx Pharmaceuticals Inc. United States

Our vision is to provide effective and safe RNA therapeutics to patients who suffer from intractable...

Series C
94 employees
Biotechnology, Health Care
View all alternatives

FAQ About Tacit Therapeutics

Tacit Therapeutics is creating RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly-applicable and inherently non-immunogenic means to repair mutated genes.
Tacit Therapeutics was founded in 2021.
Tacit Therapeutics is headquartered in South San Francisco, United States.
Tacit Therapeutics operates in Biotechnology and Health Care. Its work centres on RNA-targeting treatments, gene therapy, genetic diseases and RNA repair. Its customers include patients with genetic diseases, healthcare providers and biotech and pharmaceutical collaborators.
Tacit Therapeutics has a B2B business model. Its revenue comes from Licensing, Performance Based and Service Fee.
Tacit Therapeutics has approximately 13 employees.
Tacit Therapeutics has completed 2 funding rounds, raising a total of $9.75M. The latest funding stage is Venture round.
Tacit Therapeutics offers: RNA trans-splicing therapies, Splicing-Directed Repair technology.
Top alternatives and competitors to Tacit Therapeutics include Alltrna, Orchard Therapeutics - U.S., ADARx Pharmaceuticals Inc., Modalis Therapeutics, Nephrogen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tacit Therapeutics and Alltrna are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tacit Therapeutics, https://bouncewatch.com/company/tacit-therapeutics, updated 9 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout